Reaping the prevention benefits of highly active antiretroviral treatment

Policy implications of HIV Prevention Trials Network 052

Andrew D. Forsyth, Ronald Valdiserri

Research output: Contribution to journalReview article

Abstract

Purpose of review: This review explores the policy implications of findings from the HIV Prevention Trials Network (HPTN 052) treatment as prevention (TasP) study. Recent findings: To date, the potential of antiretrovirals to prevent sexual transmission of HIV by infected persons has been grounded in observational cohort, ecological, mathematical modeling, and meta-analytic studies. HPTN 052 represents the first randomized controlled trial to test the secondary prevention benefit of HIV transmission using antiretroviral treatment in largely asymptomatic persons with high CD4 cell counts. Summary: The US National HIV/AIDS Strategy has among its key goals the reduction of incident HIV infections, improved access to quality care and associated outcomes, and the reduction in HIV-associated health disparities and inequities. HPTN 052 demonstrates that providing TasP, in combination with other effective prevention strategies offers the promise of achieving these life-saving goals. But HPTN 052 also highlights the need for cautious optimism and underscores the importance of addressing current gaps in the HIV prevention, treatment, and care continuum in order for 'TasP' strategies to achieve their full potential. Among these are necessary improvements in the capacity to expand HIV testing, facilitate effective linkage and retention in care, and improve treatment initiation, maintenance, and virus suppression.

Original languageEnglish (US)
Pages (from-to)111-116
Number of pages6
JournalCurrent Opinion in HIV and AIDS
Volume7
Issue number2
DOIs
StatePublished - Mar 2012
Externally publishedYes

Fingerprint

HIV
Therapeutics
Continuity of Patient Care
Quality of Health Care
CD4 Lymphocyte Count
Secondary Prevention
HIV Infections
Acquired Immunodeficiency Syndrome
Randomized Controlled Trials
Maintenance
Viruses
Health

Keywords

  • antiretrovirals
  • policy
  • prevention
  • sexual transmission

ASJC Scopus subject areas

  • Immunology
  • Hematology
  • Oncology
  • Oncology(nursing)
  • Infectious Diseases
  • Virology

Cite this

Reaping the prevention benefits of highly active antiretroviral treatment : Policy implications of HIV Prevention Trials Network 052. / Forsyth, Andrew D.; Valdiserri, Ronald.

In: Current Opinion in HIV and AIDS, Vol. 7, No. 2, 03.2012, p. 111-116.

Research output: Contribution to journalReview article

@article{1dee2ccc6baa489985563c015ac580ce,
title = "Reaping the prevention benefits of highly active antiretroviral treatment: Policy implications of HIV Prevention Trials Network 052",
abstract = "Purpose of review: This review explores the policy implications of findings from the HIV Prevention Trials Network (HPTN 052) treatment as prevention (TasP) study. Recent findings: To date, the potential of antiretrovirals to prevent sexual transmission of HIV by infected persons has been grounded in observational cohort, ecological, mathematical modeling, and meta-analytic studies. HPTN 052 represents the first randomized controlled trial to test the secondary prevention benefit of HIV transmission using antiretroviral treatment in largely asymptomatic persons with high CD4 cell counts. Summary: The US National HIV/AIDS Strategy has among its key goals the reduction of incident HIV infections, improved access to quality care and associated outcomes, and the reduction in HIV-associated health disparities and inequities. HPTN 052 demonstrates that providing TasP, in combination with other effective prevention strategies offers the promise of achieving these life-saving goals. But HPTN 052 also highlights the need for cautious optimism and underscores the importance of addressing current gaps in the HIV prevention, treatment, and care continuum in order for 'TasP' strategies to achieve their full potential. Among these are necessary improvements in the capacity to expand HIV testing, facilitate effective linkage and retention in care, and improve treatment initiation, maintenance, and virus suppression.",
keywords = "antiretrovirals, policy, prevention, sexual transmission",
author = "Forsyth, {Andrew D.} and Ronald Valdiserri",
year = "2012",
month = "3",
doi = "10.1097/COH.0b013e32834fcff6",
language = "English (US)",
volume = "7",
pages = "111--116",
journal = "Current Opinion in HIV and AIDS",
issn = "1746-630X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Reaping the prevention benefits of highly active antiretroviral treatment

T2 - Policy implications of HIV Prevention Trials Network 052

AU - Forsyth, Andrew D.

AU - Valdiserri, Ronald

PY - 2012/3

Y1 - 2012/3

N2 - Purpose of review: This review explores the policy implications of findings from the HIV Prevention Trials Network (HPTN 052) treatment as prevention (TasP) study. Recent findings: To date, the potential of antiretrovirals to prevent sexual transmission of HIV by infected persons has been grounded in observational cohort, ecological, mathematical modeling, and meta-analytic studies. HPTN 052 represents the first randomized controlled trial to test the secondary prevention benefit of HIV transmission using antiretroviral treatment in largely asymptomatic persons with high CD4 cell counts. Summary: The US National HIV/AIDS Strategy has among its key goals the reduction of incident HIV infections, improved access to quality care and associated outcomes, and the reduction in HIV-associated health disparities and inequities. HPTN 052 demonstrates that providing TasP, in combination with other effective prevention strategies offers the promise of achieving these life-saving goals. But HPTN 052 also highlights the need for cautious optimism and underscores the importance of addressing current gaps in the HIV prevention, treatment, and care continuum in order for 'TasP' strategies to achieve their full potential. Among these are necessary improvements in the capacity to expand HIV testing, facilitate effective linkage and retention in care, and improve treatment initiation, maintenance, and virus suppression.

AB - Purpose of review: This review explores the policy implications of findings from the HIV Prevention Trials Network (HPTN 052) treatment as prevention (TasP) study. Recent findings: To date, the potential of antiretrovirals to prevent sexual transmission of HIV by infected persons has been grounded in observational cohort, ecological, mathematical modeling, and meta-analytic studies. HPTN 052 represents the first randomized controlled trial to test the secondary prevention benefit of HIV transmission using antiretroviral treatment in largely asymptomatic persons with high CD4 cell counts. Summary: The US National HIV/AIDS Strategy has among its key goals the reduction of incident HIV infections, improved access to quality care and associated outcomes, and the reduction in HIV-associated health disparities and inequities. HPTN 052 demonstrates that providing TasP, in combination with other effective prevention strategies offers the promise of achieving these life-saving goals. But HPTN 052 also highlights the need for cautious optimism and underscores the importance of addressing current gaps in the HIV prevention, treatment, and care continuum in order for 'TasP' strategies to achieve their full potential. Among these are necessary improvements in the capacity to expand HIV testing, facilitate effective linkage and retention in care, and improve treatment initiation, maintenance, and virus suppression.

KW - antiretrovirals

KW - policy

KW - prevention

KW - sexual transmission

UR - http://www.scopus.com/inward/record.url?scp=84857362322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857362322&partnerID=8YFLogxK

U2 - 10.1097/COH.0b013e32834fcff6

DO - 10.1097/COH.0b013e32834fcff6

M3 - Review article

VL - 7

SP - 111

EP - 116

JO - Current Opinion in HIV and AIDS

JF - Current Opinion in HIV and AIDS

SN - 1746-630X

IS - 2

ER -